More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product. Oral tumor treatment vimseltinib passed the ...

On a bad day for the stock market overall, Deciphera Pharmaceuticals (NASDAQ: DCPH) was quite the happy standout. Shares of the biotech closed more than 12% higher on Tuesday thanks to the launch of a ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -Deciphera Pharmaceuticals said on Monday Japan's Ono Pharmaceutical Co will acquire the cancer drugmaker for $2.4 ...

Deciphera Pharmaceuticals has posted data from a phase 1 trial of its small molecule switch control inhibitor of CSF1R, DCC-3014. The early-phase data have emboldened Deciphera to expand the trial to ...

The company reported $42.1 million in revenue for 2020, up from $25 million in 2019. Qinlock (ripretinib) was responsible for most of that revenue, including $38 million in the U.S. and $1.5 million ...

– Third Quarter 2021 Revenue of $23.2 Million, Including QINLOCK® (ripretinib) Net Product Revenue of $21.7 Million – – Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Patients with ...

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has recently experienced a daily loss of 2.19% and a 3-month loss of 10.22%. The company's Earnings Per Share (EPS) (EPS) also indicate a loss of 2.32.

Long-established in the Drug Manufacturers industry, Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has enjoyed a stellar reputation. However, it has recently witnessed a daily loss of 2.19%, juxtaposed ...

Deciphera Pharmaceuticals, Inc. DCPH announced that it has dosed the first patient in a phase I study which is evaluating its investigational ULK kinase inhibitor, DCC-3116, for the treatment of ...

The late Steve Allen, creator of TV’s Tonight Show, song writer and musician, wrote the popular song “This Could Be The Start Of Something Big.” Today’s news story reporting Eli Lilly has entered into ...